Trifork Group AG
23/2025・Trifork Group: Reporting of transactions made by persons discharging managerial responsibilities
23/2025・Trifork Group: Reporting of transactions made by persons discharging managerial responsibilities
Company announcement no. 23 / 2025
Schindellegi, Switzerland – 25 April 2025
Reporting of transactions made by persons discharging managerial responsibilities
Pursuant to the Market Abuse Regulation Article 19, Trifork Group AG (Swiss company registration number CHE-474.101.854) (“Trifork”) hereby notifies receipt of information of the following transactions made by persons discharging managerial responsibilities in Trifork in connection with fixed salaries paid in shares. Reference is made to company announcement no. 1/2025 on 21 January 2025.
| 1. | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name | Jørn Larsen | |
| 2. | Reason for the notification | ||
| a) | Position/status | CEO | |
| b) | Initial notification/ Amendment | Initial notification | |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Trifork Group AG | |
| b) | LEI | 8945004BYZKXPESTBL36 | |
| 4.1 | Details of the transaction(s) | ||
| a) | Description of the financial instrument, type of instrument Identification code | Shares ISIN CH1111227810 | |
| b) | Nature of the transaction | A share of 25% of the fixed monthly salary is paid out in shares as described in the company announcement no. 1/2025. | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| DKK 0 | 1,245 | ||
| d) | Aggregated information — Aggregated volume — Price | N/A | |
| e) | Date of the transaction | 25 April 2025 | |
| f) | Place of the transaction | Outside a trading venue | |
| 1. | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name | Kristian Wulf-Andersen | |
| 2. | Reason for the notification | ||
| a) | Position/status | CFO | |
| b) | Initial notification/ Amendment | Initial notification | |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Trifork Group AG | |
| b) | LEI | 8945004BYZKXPESTBL36 | |
| 4.1 | Details of the transaction(s) | ||
| a) | Description of the financial instrument, type of instrument Identification code | Shares ISIN CH1111227810 | |
| b) | Nature of the transaction | A share of 10% of the fixed monthly salary is paid out in shares as described in the company announcement no. 1/2025. | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| DKK 0 | 332 | ||
| d) | Aggregated information — Aggregated volume — Price | N/A | |
| e) | Date of the transaction | 25 April 2025 | |
| f) | Place of the transaction | Outside a trading venue | |
Investor and media contact
Frederik Svanholm, Group Investment Director, frsv@trifork.com, +41 79 357 73 17
About Trifork
Trifork is a pioneering global technology partner, empowering enterprise and public sector customers with innovative solutions. With 1,229 professionals across 73 business units in 16 countries, Trifork delivers expertise in inspiring, building, and running advanced software solutions across diverse sectors, including public administration, healthcare, manufacturing, logistics, energy, financial services, retail, and real estate. Trifork Labs, the Group’s R&D hub, drives innovation by investing in and developing synergistic and high-potential technology companies. Trifork Group AG is a publicly listed company on Nasdaq Copenhagen. Learn more at trifork.com.
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
BioPorto A/S25.4.2025 13:55:38 CEST | Press release
Managers’ transactions
BioPorto A/S25.4.2025 13:55:38 CEST | Pressemeddelelse
Ledende medarbejderes transaktioner
BioPorto A/S25.4.2025 13:45:33 CEST | Press release
BioPorto A/S raises DKK 33.5 million in new capital round - Change of number of shares and votes
BioPorto A/S25.4.2025 13:45:33 CEST | Pressemeddelelse
BioPorto A/S rejser 33,5 mio. kr. i ny kapitalrunde - Ændring i antal aktier og stemmer
Junshi Biosciences25.4.2025 13:43:50 CEST | Press release
Junshi Biosciences Announces the sNDA Approval of Toripalimab for the 1st-line Treatment of Melanoma
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom